No connection

Search Results

ABBV vs NAMS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
NAMS
NewAmsterdam Pharma Company N.V.
BEARISH
Price
$34.44
Market Cap
$3.96B
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
ABBV
163.63
NAMS
--
Forward P/E
ABBV
15.42
NAMS
-25.23
P/B Ratio
ABBV
-146.66
NAMS
5.76
P/S Ratio
ABBV
6.5
NAMS
175.97
EV/EBITDA
ABBV
15.27
NAMS
-14.74

Profitability

Gross Margin
ABBV
71.46%
NAMS
100.0%
Operating Margin
ABBV
35.5%
NAMS
-206188.0%
Profit Margin
ABBV
4.0%
NAMS
0.0%
ROE
ABBV
137.96%
NAMS
-28.29%
ROA
ABBV
9.59%
NAMS
-17.27%

Growth

Revenue Growth
ABBV
9.1%
NAMS
-99.8%
Earnings Growth
ABBV
-88.7%
NAMS
--

Financial Health

Debt/Equity
ABBV
--
NAMS
0.0
Current Ratio
ABBV
0.72
NAMS
7.88
Quick Ratio
ABBV
0.47
NAMS
7.69

Dividends

Dividend Yield
ABBV
3.05%
NAMS
--
Payout Ratio
ABBV
490.15%
NAMS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
NAMS BEARISH

NAMS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating very weak financial health. Despite a 'Strong Buy' analyst consensus and a high current ratio of 7.88, the company has suffered a catastrophic revenue collapse of -99.80% YoY and trades at an unsustainable Price/Sales ratio of 175.97. The stark disconnect between the bullish analyst targets and the bearish insider selling ($46.22M in sales) suggests a high-risk speculative profile. While zero debt provides a temporary safety net, the operational metrics are currently non-viable.

Strengths
Zero debt (Debt/Equity: 0.00)
Strong short-term liquidity (Current Ratio: 7.88)
High Gross Margin (100.00%)
Risks
Catastrophic revenue decline (-99.80% YoY)
Extreme valuation premium (P/S ratio of 175.97)
Severe operational losses (Operating Margin: -206,187.50%)

Compare Another Pair

ABBV vs NAMS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and NewAmsterdam Pharma Company N.V. (NAMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile